| Disease | PHARMACOKINETICS AND THE EBT WERE NOT SIGNIFICANTLY DIFFERENT FROM THOSE OF ONE GLASS OF DS GFJ.
CONSUMPTION OF ONE GLASS OF DS GFJ SIGNIFICANTLY INCREASED THE AUC AND SMAX OF MIDAZOLAM APPROXIMATELY 2-FOLD WITHOUT A SIGNIFICANT EFFECT ON THE T1/2 OF MIDAZOLAM OR THE EBT. THE EFFECTS OF CONSUMING ONE GLASS OF SS GFJ ON MIDAZOLAM
OF GLASS OF DS GFJ THREE TIMES DAILY FOR 3 DAYS INCREASED THE CMAX OF MIDAZOLAM 3-FOLD, THE AUC 6 FOLD, AND THE T 1/2 2-FOLD AND DECREASED THE AMOUNT OF EXHALED 14CO2 IN ALL 8 SUBJECTS, WITH A MEAN DECREASE IN EBT OF 18%. IN PHASE II,
ERYTHROMYCIN (0.03 MG). THE EBT WAS PERFORMED 20 MINUTES FOLLOWING ERYTHROMYCIN ADMINISTRATION.BLOOD WAS COLLECTED DURING THE 24 HOURS FOLLOWING PROBE DRUG ADMINISTRATION FOR THE ANALYSIS OF MIDAZOLAM PHARMACOKINETICS. IN PHASE I, CONSUMPTION
SINGLE-STRENGTH(SS) GFJ, (2) DS GFJ, AND (3) WATER PLACEBO. PROBE DRUGS, ADMINISTERED 30 MINUTES OR 1 HOUR FOLLOWING EACH TREATMENT IN PHASE I OR II, RESPECTIVELY, CONSISTED OF ORAL MIDAZOLAM (2 MG) CO-ADMINISTERED WITH IV (14G N-METHYL-
WATER (PLACEBO) OR DOUBLE-STRENGTH (DS) GFJ TID FOR 2 DAYS AND THEN 90,60, AND 30 MINUTES PRIOR TO ADMINISTRATION OF PROBE DRUGS ON THE 3RD DAY. IN PHASE II, 16 MALE VULUNTEERS WERE RANDOMIZED TO THE ORDER OF RECEIVING ONE GLASS OF (1)
THIS STUDY COMPARED THE EFFECTS OF CONSUMING LARGE QUANTITIES AND MORE TYPICAL AMOUNTS OF GFJ ON THE ACTIVITY OF HEPATIC AND INTESTINAL CYTOCHROME. IN PHASE I, 8 MALE VOLUNTEERS WERE RANDOMIZED TO THE ORDER OF RECEIVING ONE GLASS (240 ML) OF |